IRADIMED Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
IRADIMED verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 26.5%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 10.4%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 17.9%. Die Eigenkapitalrendite von IRADIMED beträgt 23.8% und die Nettomargen betragen 26.8%.
Wichtige Informationen
26.48%
Wachstumsrate der Gewinne
25.97%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | 8.90% |
| Wachstumsrate der Einnahmen | 17.86% |
| Eigenkapitalrendite | 23.76% |
| Netto-Marge | 26.82% |
| Letzte Ertragsaktualisierung | 31 Mar 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
IRMD: 2026 Dividend And Guidance Will Anchor Bullish Re Rating
Analysts nudged their price targets for IRADIMED higher, with recent Street research citing supportive views on the business. These views help explain the updated fair value of $118.67 along with a slightly adjusted discount rate and forward P/E assumptions.IRMD: 2026 Dividend And Guidance Will Support Bullish Re-Rating
Analysts have trimmed their fair value estimate for IRADIMED from about $120 to roughly $118.67, citing revised assumptions for revenue growth, profit margins and future P/E. At the same time, recent Street research, including fresh bullish initiations and higher price targets, continues to support a constructive view on the stock.IRMD: 2026 Guidance And Dividend Will Support Higher Price Re-Rating
Analysts have lifted their price target on IRADIMED by a double digit dollar amount, citing updated valuation work that reflects refined assumptions, including a fair value of $120, a discount rate of 7.69%, revenue growth of 9.70%, a profit margin of 27.77% and a future P/E of 58.53. Analyst Commentary Recent research points to a tighter alignment between IRADIMED's valuation work and updated assumptions on growth, profitability and the P/E investors may be willing to pay.IRMD: 2026 Guidance And Dividend Will Support Higher P/E Repricing
Narrative Update on IRADIMED The analyst price target on IRADIMED has been raised by $20 to $120. Analysts cite updated valuation work that incorporates a slightly higher discount rate and future P/E assumption, along with recent Street research that supports the new level.IRMD: 2026 Guidance And Dividends Will Support Higher Earnings Multiple
Analysts have lifted their fair value estimate for IRADIMED from $99 to $120, citing updated assumptions around slightly different revenue growth, profit margin expectations, discount rate, and a higher future P/E. These revisions align with recent Street price target increases reported by firms such as Lake Street and Roth Capital.IRMD: Stable Outlook Will Rely On 2026 Guidance And Dividend Support
Analysts have kept their price target for IRADIMED effectively unchanged at $99.00. They cite only marginal tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions rather than any shift in their core view on the company.IRMD: Record Backlog And Raised Guidance Will Support Premium Yet Balanced Outlook
Narrative Update Analysts have nudged their price targets for IRADIMED higher into a US$98 to US$100 range, reflecting updated forward estimates, a record backlog, the recent beat and raise quarter, and expectations tied to the 3870 IV Pump launch. Analyst Commentary Analysts updating their models for IRADIMED are broadly constructive, with recent research focused on how the latest quarter and product pipeline translate into earnings power and valuation support.IRMD: Raised Guidance And Backlog Support Premium While Risks Keep Outlook Balanced
Narrative Update Introduction Analysts have lifted their price expectations for IRADIMED to a range of about $98 to $100, citing higher forward estimates, a record backlog that supports near term visibility, and confidence around the 3870 IV Pump launch as key reasons for the updated targets. Analyst Commentary Recent Street research on IRADIMED reflects a clear tilt toward optimism, with price targets lifted into the high double digits following the latest quarterly update.IRMD: Raised Guidance And Backlog Will Support Premium Amid Execution Risks
Analysts have nudged their average price target on IRADIMED higher, to a level just under $100 per share from the low $90s, citing stronger than expected Q3 results, raised full year guidance, and growing confidence that a robust backlog and upcoming product launches will support sustained growth. Analyst Commentary Bullish analysts highlight that the recent upside surprise on both revenue and earnings, along with raised full year guidance, reinforces a view that IRADIMED is executing ahead of prior expectations and can support a higher valuation multiple.IRMD: Raised Guidance And Strong Backlog Will Maintain Premium Despite Execution Risks
IRADIMED’s analyst price target has been raised from $90 to a range approaching $100 per share. Analysts cite the company’s recent sales and earnings outperformance, increased full-year guidance, and strong prospects from product innovation and backlog growth.IRMD: Raised Guidance And Record Backlog Are Set To Drive Continued Momentum
Analysts have raised their price target for IRADIMED significantly, from $82.50 to $99.00. They cited stronger-than-expected quarterly results, improved guidance, and a robust outlook driven by a growing backlog and product innovation.IRMD: Index Addition and Strong Margins Will Support Measured Upside
Analysts have raised their price target for IRADIMED from $73.50 to $82.50. They cite modest improvements in projected profit margins and valuation multiples as key drivers behind the adjustment.Should You Be Adding IRADIMED (NASDAQ:IRMD) To Your Watchlist Today?
Oct 09
IRADIMED CORPORATION's (NASDAQ:IRMD) Shares Climb 27% But Its Business Is Yet to Catch Up
Aug 13IRADIMED's (NASDAQ:IRMD) Profits May Not Reveal Underlying Issues
Aug 08Shareholders Would Enjoy A Repeat Of IRADIMED's (NASDAQ:IRMD) Recent Growth In Returns
Jun 01
Innovative IV Pumps And Monitor Expansion Set To Spearhead Revenue Surge And Enhance Profit Margins
Introduction of the new 3870 IV pump and expansion in the Monitor business signal potential significant revenue growth and increases in product line revenue.IRADIMED's (NASDAQ:IRMD) Solid Profits Have Weak Fundamentals
Aug 08If EPS Growth Is Important To You, IRadimed (NASDAQ:IRMD) Presents An Opportunity
Feb 23Getting In Cheap On IRadimed Corporation (NASDAQ:IRMD) Is Unlikely
Feb 07Should You Investigate IRadimed Corporation (NASDAQ:IRMD) At US$45.06?
Nov 06Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)
Oct 13At US$41.26, Is It Time To Put IRadimed Corporation (NASDAQ:IRMD) On Your Watch List?
Feb 05Iradimed withdraws FDA filing for new infusion pump; prelim Q3 revenue rises 13% Y/Y
Oct 10IRadimed: Record Revenue Could Translate To Share Price Appreciation
Aug 23Aufschlüsselung der Einnahmen und Ausgaben
Wie IRADIMED Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 31 Dec 25 | 84 | 22 | 35 | 3 |
| 30 Sep 25 | 81 | 21 | 34 | 3 |
| 30 Jun 25 | 78 | 21 | 33 | 3 |
| 31 Mar 25 | 75 | 20 | 33 | 3 |
| 31 Dec 24 | 73 | 19 | 32 | 3 |
| 30 Sep 24 | 71 | 19 | 31 | 3 |
| 30 Jun 24 | 69 | 19 | 30 | 3 |
| 31 Mar 24 | 68 | 18 | 28 | 3 |
| 31 Dec 23 | 66 | 17 | 27 | 3 |
| 30 Sep 23 | 63 | 16 | 26 | 3 |
| 30 Jun 23 | 60 | 15 | 25 | 3 |
| 31 Mar 23 | 56 | 14 | 25 | 3 |
| 31 Dec 22 | 53 | 13 | 23 | 2 |
| 30 Sep 22 | 50 | 13 | 23 | 2 |
| 30 Jun 22 | 48 | 12 | 22 | 2 |
| 31 Mar 22 | 45 | 10 | 21 | 2 |
| 31 Dec 21 | 42 | 9 | 20 | 2 |
| 30 Sep 21 | 38 | 6 | 17 | 2 |
| 30 Jun 21 | 35 | 5 | 17 | 2 |
| 31 Mar 21 | 32 | 1 | 19 | 2 |
| 31 Dec 20 | 32 | 1 | 20 | 2 |
| 30 Sep 20 | 34 | 4 | 23 | 2 |
| 30 Jun 20 | 36 | 5 | 23 | 2 |
| 31 Mar 20 | 39 | 10 | 20 | 1 |
| 31 Dec 19 | 39 | 10 | 20 | 1 |
| 30 Sep 19 | 36 | 8 | 18 | 1 |
| 30 Jun 19 | 34 | 8 | 17 | 1 |
| 31 Mar 19 | 32 | 7 | 16 | 1 |
| 31 Dec 18 | 30 | 6 | 16 | 2 |
| 30 Sep 18 | 29 | 5 | 15 | 1 |
| 30 Jun 18 | 27 | 3 | 15 | 2 |
| 31 Mar 18 | 25 | 2 | 15 | 2 |
| 31 Dec 17 | 23 | 0 | 15 | 2 |
| 30 Sep 17 | 22 | 1 | 14 | 2 |
| 30 Jun 17 | 24 | 3 | 13 | 2 |
| 31 Mar 17 | 29 | 5 | 14 | 2 |
| 31 Dec 16 | 32 | 7 | 14 | 1 |
| 30 Sep 16 | 35 | 8 | 15 | 1 |
| 30 Jun 16 | 35 | 9 | 14 | 2 |
| 31 Mar 16 | 33 | 8 | 13 | 2 |
| 31 Dec 15 | 31 | 8 | 12 | 2 |
| 30 Sep 15 | 26 | 5 | 11 | 2 |
| 30 Jun 15 | 22 | 4 | 10 | 1 |
Qualität der Erträge: IRMD hat hohe Qualitätseinkünfte.
Wachsende Gewinnspanne: IRMDDie aktuellen Gewinnspannen (26.8%) sind höher als im letzten Jahr (26.3%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: IRMDIn den letzten 5 Jahren sind die Einnahmen von 26.5% pro Jahr erheblich gestiegen.
Beschleunigtes Wachstum: IRMDDas Gewinnwachstum des Unternehmens im letzten Jahr (16.9%) liegt unter seinem 5-Jahres-Durchschnitt (26.5% pro Jahr).
Erträge im Vergleich zur Industrie: IRMD Das Gewinnwachstum im vergangenen Jahr (16.9%) übertraf das der Branche Medical Equipment 13.2% .
Eigenkapitalrendite
Hohe Eigenkapitalrendite: IRMDDie Eigenkapitalrendite des Unternehmens (23.8%) wird als hoch angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/04 13:02 |
| Aktienkurs zum Tagesende | 2026/05/04 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
IRADIMED CORPORATION wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Lawrence Solow | CJS Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Frank Takkinen | Lake Street Capital Markets, LLC |